Study treatment
Tumors, toxicity, Tumor
TUMORS, DISEASE PROGRESSION, TUMOR
Patients received oral pemigatinib at 13.5 mg once daily every 3 weeks on an intermittent 2-weeks-on/1-week-off dosing schedule. Tumor response was assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 every 9 weeks after first dosing. If the patients were considered benefiting from the treatment by the investigator, pemigatinib could be continued until disease progression, unacceptable toxicity, initiation of other anti-tumor therapy, or for a maximum of 2-year treatment.